The U.S. Food and Drug Administration (FDA) has issued one of its most serious medical device safety classifications involving Boston Scientific’s ACCOLADE family of pacemakers and cardiac resynchronization therapy pacemakers (CRT-Ps), a development that is sending renewed concern throughout the U.S. cardiovascular device market and hospital procurement sector.
The correction, officially classified by the FDA as a Class I recall, affects ACCOLADE pacemakers, PROPONENT, ESSENTIO, ALTRUA 2 dual chamber standard life devices, and VISIONIST and VALITUDE CRT-P systems manufactured by Boston Scientific. The agency warned that the affected devices could enter “Safety Mode” unexpectedly because of battery-related high impedance issues, potentially resulting in pacing interruptions, loss of telemetry communication, or the need for premature replacement surgery.
Although the recall does not require devices to be removed from patients immediately, the FDA emphasized that continued use without corrective action could lead to serious injury or death. The agency confirmed that the issue has already been associated with multiple patient injuries and deaths.
The correction stems from a long-running battery impedance problem first identified in subsets of Boston Scientific pacemakers in late 2024. According to FDA recall documentation, affected devices may experience repeated power-on resets caused by abnormal battery behavior. If three resets occur within a 48-hour period, the device automatically enters Safety Mode, a backup operating state designed to preserve essential pacing functions during severe internal malfunctions.
However, once Safety Mode is activated, the pacemaker cannot return to normal operation. In some patients, this may lead to reduced pacing support, unipolar pacing behavior, interrupted telemetry communication, and inaccurate battery status reporting. These risks are particularly serious for pacemaker-dependent patients who rely on uninterrupted cardiac rhythm management.
On March 19, 2026, Boston Scientific issued an Urgent Medical Device Correction advising physicians and hospitals that its new Brady Software Maintenance Release 6 (SMR6) update was available to mitigate the problem. The software update is intended to reduce the likelihood of devices entering Safety Mode in ambulatory settings due to battery impedance abnormalities while also correcting unintended software behaviors introduced during a previous software revision known as Brady SMR5.
The FDA formally classified the correction as a Class I recall on May 7, 2026, expanding the scope of the affected population to include additional CRT-P and dual-chamber extended life devices. According to FDA records, the agency considers this the highest level of recall classification because of the potential for life-threatening adverse events.
The impact on the U.S. surgical and hospital supply chain is significant.
Pacemakers and CRT-P systems represent critical implantable cardiac technologies used daily in electrophysiology labs, cardiac surgery departments, and interventional cardiology programs across the country. Hospitals now face increased operational pressure as they work to identify affected inventory, coordinate software updates, assess patient monitoring schedules, and prepare for the possibility of accelerated generator replacement procedures.
For supply chain managers, the issue reinforces growing concerns around device lifecycle reliability and post-market surveillance in high-dependency implantable technologies.
Unlike many disposable surgical products, implantable cardiac devices carry long-term patient monitoring obligations. When recalls or corrective actions occur, hospitals must not only manage inventory exposure but also coordinate patient communication, physician review, software servicing, and potential surgical intervention.
The recall also arrives during a period of heightened scrutiny surrounding medical device safety and battery performance reliability. The FDA has increasingly relied on “Early Alerts” and corrective-action classifications to communicate risks more rapidly before widespread device failure occurs. Analysts say this reflects a broader regulatory shift toward proactive post-market oversight.
According to the FDA, Boston Scientific has reported four deaths and more than 2,500 serious injuries associated with the issue as of March 2026. These figures include incidents linked to high battery impedance, Safety Mode activation, telemetry disablement, and software-related unintended behaviors.
The Heart Rhythm Society (HRS) also issued updated safety communications supporting the SMR6 software rollout while advising physicians to closely monitor affected patients. HRS stated that the revised software is intended to resolve incomplete ZIP telemetry disablement behavior and reduce risks associated with prior software versions.
For electrophysiology departments and hospital procurement teams, the financial implications may also become substantial.
Software upgrades, increased follow-up visits, remote monitoring assessments, and potential elective replacements all contribute to higher operational costs. Hospitals with large implant populations may experience elevated staffing demands as cardiac rhythm teams coordinate device interrogations and patient scheduling.
Industry analysts note that recalls involving implantable cardiac rhythm devices can also influence future purchasing behavior among integrated delivery networks (IDNs), hospital systems, and group purchasing organizations (GPOs). Procurement leaders increasingly evaluate manufacturers not only on innovation and pricing, but also on:
• Long-term device reliability
• Recall frequency
• Software update management
• Cybersecurity and telemetry stability
• Clinical support responsiveness
• Replacement logistics
This trend is becoming especially important as hospitals seek to reduce operational disruptions and long-term liability exposure tied to implantable technologies.
The Boston Scientific correction additionally highlights the growing role of software in modern cardiac devices. Today’s implantable pacemakers are deeply integrated with telemetry systems, remote monitoring platforms, firmware updates, and wireless communication infrastructure. While these advancements improve patient oversight, they also create new categories of software-related risk that hospitals must manage alongside traditional hardware concerns.
According to recent reporting from MassDevice, the FDA’s latest recall action also expands the affected device population while introducing additional mitigation strategies through the updated Brady SMR6 release. The publication noted that the FDA specifically cited unintended behaviors linked to the previous SMR5 software update, including inaccurate battery test interpretation and prolonged voltage recovery states.
Skyler Rivera of MassDevice reported that the FDA’s expanded Class I recall introduces a broader software mitigation effort aimed at reducing ambulatory Safety Mode activation risks in affected pacemakers. Rivera also noted that the correction expands the recall scope to include additional ACCOLADE CRT-P and DR-EL devices after ongoing review of battery impedance performance trends.
